Journal article

CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants

Tim Carver, Simon Hartley, Andrew Lee, Alex P Cunningham, Stephanie Archer, Chantal Babb de Villiers, Jonathan Roberts, Rod Ruston, Fiona M Walter, Marc Tischkowitz, Douglas F Easton, Antonis C Antoniou



BACKGROUND: The CanRisk Tool ( is the next-generation web interface for the latest version of the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) state-of-the-art risk model and a forthcoming ovarian cancer risk model. METHODS: The tool captures information on family history, rare pathogenic variants in cancer susceptibility genes, polygenic risk scores, lifestyle/hormonal/clinical features, and imaging risk factors to predict breast and ovarian cancer risks and estimate the probabilities of carrying pathogenic variants in certain genes. It was implemented using modern web frameworks, technologies, and web services to make it e..

View full abstract

University of Melbourne Researchers


Awarded by Cancer Research UK

Awarded by European Union

Awarded by Wellcome Trust Collaborative Award

Awarded by PERSPECTIVE programme: The Government of Canada through Canadian Institutes of Health Research

Funding Acknowledgements

This work was supported by Cancer Research UKgrants (C12292/A20861, to A.C. Antoniou and C1287/A16563, to D.F. Easton); the European Union's Horizon 2020 research and innovation programme under grant agreement numbers 633784 (BCAST to M. Schmidt) and 634935 (BRIDGES, to P. Devilee); a Wellcome Trust Collaborative Award (203477/B/16/Z, to S.H. Teo); and the PERSPECTIVE programme: The Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344), the Ministere de l'Economie, de la Science et de l'Innovation du Quebec through Genome Quebec, and the Quebec Breast Cancer Foundation to J. Simard. F.M. Walter is Director of the multiinstitutional CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385).